Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice

Julia L. Gregory, Claudia M. Prada, Sara J. Fine, Monica Garcia-Alloza, Rebecca Betensky, Michal Arbel-Ornath, Steven M. Greenberg, Brian J. Bacskai, Matthew P. Frosch

Research output: Contribution to journalArticle

Abstract

Cerebral amyloid angiopathy (CAA), the accumulation of βamyloid (Aβ) in the walls of leptomeningeal and cortical blood vessels of the brain, is a major cause of intracerebral hemorrhage and cognitive impairment and is commonly associated with Alzheimer disease. The progression of CAA, as measured in transgenic mice by longitudinal imaging with multiphoton microscopy, occurs in a predictable linear manner. The dynamics of Aβ deposition in and clearance from vascular walls and their relationship to the concentration of Aβ in the brain are poorly understood. We manipulated AA levels in the brain using 2 approaches: peripheral clearance via administration of the amyloid binding "peripheral sink" protein gelsolin and direct inhibition of its formation via administration of LY-411575, a smallmolecule γ-secretase inhibitor. We found that gelsolin and LY-411575 both reduced the rate of CAA progression in Tg2576 mice from untreated rates of 0.58% ± 0.15% and 0.52% ± 0.09% to 0.11% T 0.18% (p = 0.04) and j0.17% ± 0.09% (p < 0.001) of affected vessel per day, respectively, in the absence of an immune response. The progression of CAA was also halted when gelsolin was combined with LY-411575 (j0.004% ± 0.10%, p < 0.003). These data suggest that CAA progression can be prevented with non-immune approaches that may reduce the availability of soluble Aβ but without evidence of substantial amyloid clearance from vessels.

Original languageEnglish (US)
Pages (from-to)1009-1017
Number of pages9
JournalJournal of Neuropathology and Experimental Neurology
Volume71
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Cerebral Amyloid Angiopathy
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Amyloid
Transgenic Mice
Gelsolin
Blood Vessels
Brain
Amyloid Precursor Protein Secretases
Cerebral Hemorrhage
Microscopy
Alzheimer Disease

Keywords

  • Alzheimer
  • Amyloid
  • Cerebral amyloid angiopathy
  • Cerebrovasculature
  • Gamma secretase
  • Gelsolin
  • Imaging
  • Multiphoton

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Gregory, J. L., Prada, C. M., Fine, S. J., Garcia-Alloza, M., Betensky, R., Arbel-Ornath, M., ... Frosch, M. P. (2012). Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. Journal of Neuropathology and Experimental Neurology, 71(11), 1009-1017. https://doi.org/10.1097/NEN.0b013e3182729845

Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. / Gregory, Julia L.; Prada, Claudia M.; Fine, Sara J.; Garcia-Alloza, Monica; Betensky, Rebecca; Arbel-Ornath, Michal; Greenberg, Steven M.; Bacskai, Brian J.; Frosch, Matthew P.

In: Journal of Neuropathology and Experimental Neurology, Vol. 71, No. 11, 01.11.2012, p. 1009-1017.

Research output: Contribution to journalArticle

Gregory, JL, Prada, CM, Fine, SJ, Garcia-Alloza, M, Betensky, R, Arbel-Ornath, M, Greenberg, SM, Bacskai, BJ & Frosch, MP 2012, 'Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice', Journal of Neuropathology and Experimental Neurology, vol. 71, no. 11, pp. 1009-1017. https://doi.org/10.1097/NEN.0b013e3182729845
Gregory, Julia L. ; Prada, Claudia M. ; Fine, Sara J. ; Garcia-Alloza, Monica ; Betensky, Rebecca ; Arbel-Ornath, Michal ; Greenberg, Steven M. ; Bacskai, Brian J. ; Frosch, Matthew P. / Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. In: Journal of Neuropathology and Experimental Neurology. 2012 ; Vol. 71, No. 11. pp. 1009-1017.
@article{bac4589bc345430e8335a4e4ad683782,
title = "Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice",
abstract = "Cerebral amyloid angiopathy (CAA), the accumulation of βamyloid (Aβ) in the walls of leptomeningeal and cortical blood vessels of the brain, is a major cause of intracerebral hemorrhage and cognitive impairment and is commonly associated with Alzheimer disease. The progression of CAA, as measured in transgenic mice by longitudinal imaging with multiphoton microscopy, occurs in a predictable linear manner. The dynamics of Aβ deposition in and clearance from vascular walls and their relationship to the concentration of Aβ in the brain are poorly understood. We manipulated AA levels in the brain using 2 approaches: peripheral clearance via administration of the amyloid binding {"}peripheral sink{"} protein gelsolin and direct inhibition of its formation via administration of LY-411575, a smallmolecule γ-secretase inhibitor. We found that gelsolin and LY-411575 both reduced the rate of CAA progression in Tg2576 mice from untreated rates of 0.58{\%} ± 0.15{\%} and 0.52{\%} ± 0.09{\%} to 0.11{\%} T 0.18{\%} (p = 0.04) and j0.17{\%} ± 0.09{\%} (p < 0.001) of affected vessel per day, respectively, in the absence of an immune response. The progression of CAA was also halted when gelsolin was combined with LY-411575 (j0.004{\%} ± 0.10{\%}, p < 0.003). These data suggest that CAA progression can be prevented with non-immune approaches that may reduce the availability of soluble Aβ but without evidence of substantial amyloid clearance from vessels.",
keywords = "Alzheimer, Amyloid, Cerebral amyloid angiopathy, Cerebrovasculature, Gamma secretase, Gelsolin, Imaging, Multiphoton",
author = "Gregory, {Julia L.} and Prada, {Claudia M.} and Fine, {Sara J.} and Monica Garcia-Alloza and Rebecca Betensky and Michal Arbel-Ornath and Greenberg, {Steven M.} and Bacskai, {Brian J.} and Frosch, {Matthew P.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1097/NEN.0b013e3182729845",
language = "English (US)",
volume = "71",
pages = "1009--1017",
journal = "Journal of Neuropathology and Experimental Neurology",
issn = "0022-3069",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice

AU - Gregory, Julia L.

AU - Prada, Claudia M.

AU - Fine, Sara J.

AU - Garcia-Alloza, Monica

AU - Betensky, Rebecca

AU - Arbel-Ornath, Michal

AU - Greenberg, Steven M.

AU - Bacskai, Brian J.

AU - Frosch, Matthew P.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Cerebral amyloid angiopathy (CAA), the accumulation of βamyloid (Aβ) in the walls of leptomeningeal and cortical blood vessels of the brain, is a major cause of intracerebral hemorrhage and cognitive impairment and is commonly associated with Alzheimer disease. The progression of CAA, as measured in transgenic mice by longitudinal imaging with multiphoton microscopy, occurs in a predictable linear manner. The dynamics of Aβ deposition in and clearance from vascular walls and their relationship to the concentration of Aβ in the brain are poorly understood. We manipulated AA levels in the brain using 2 approaches: peripheral clearance via administration of the amyloid binding "peripheral sink" protein gelsolin and direct inhibition of its formation via administration of LY-411575, a smallmolecule γ-secretase inhibitor. We found that gelsolin and LY-411575 both reduced the rate of CAA progression in Tg2576 mice from untreated rates of 0.58% ± 0.15% and 0.52% ± 0.09% to 0.11% T 0.18% (p = 0.04) and j0.17% ± 0.09% (p < 0.001) of affected vessel per day, respectively, in the absence of an immune response. The progression of CAA was also halted when gelsolin was combined with LY-411575 (j0.004% ± 0.10%, p < 0.003). These data suggest that CAA progression can be prevented with non-immune approaches that may reduce the availability of soluble Aβ but without evidence of substantial amyloid clearance from vessels.

AB - Cerebral amyloid angiopathy (CAA), the accumulation of βamyloid (Aβ) in the walls of leptomeningeal and cortical blood vessels of the brain, is a major cause of intracerebral hemorrhage and cognitive impairment and is commonly associated with Alzheimer disease. The progression of CAA, as measured in transgenic mice by longitudinal imaging with multiphoton microscopy, occurs in a predictable linear manner. The dynamics of Aβ deposition in and clearance from vascular walls and their relationship to the concentration of Aβ in the brain are poorly understood. We manipulated AA levels in the brain using 2 approaches: peripheral clearance via administration of the amyloid binding "peripheral sink" protein gelsolin and direct inhibition of its formation via administration of LY-411575, a smallmolecule γ-secretase inhibitor. We found that gelsolin and LY-411575 both reduced the rate of CAA progression in Tg2576 mice from untreated rates of 0.58% ± 0.15% and 0.52% ± 0.09% to 0.11% T 0.18% (p = 0.04) and j0.17% ± 0.09% (p < 0.001) of affected vessel per day, respectively, in the absence of an immune response. The progression of CAA was also halted when gelsolin was combined with LY-411575 (j0.004% ± 0.10%, p < 0.003). These data suggest that CAA progression can be prevented with non-immune approaches that may reduce the availability of soluble Aβ but without evidence of substantial amyloid clearance from vessels.

KW - Alzheimer

KW - Amyloid

KW - Cerebral amyloid angiopathy

KW - Cerebrovasculature

KW - Gamma secretase

KW - Gelsolin

KW - Imaging

KW - Multiphoton

UR - http://www.scopus.com/inward/record.url?scp=84871249596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871249596&partnerID=8YFLogxK

U2 - 10.1097/NEN.0b013e3182729845

DO - 10.1097/NEN.0b013e3182729845

M3 - Article

VL - 71

SP - 1009

EP - 1017

JO - Journal of Neuropathology and Experimental Neurology

JF - Journal of Neuropathology and Experimental Neurology

SN - 0022-3069

IS - 11

ER -